Fraser Gray, Hornet Therapeutics CEO
May 23, 2024 02:00 PM EDTUpdated 03:11 PM
Startups
R&D

UK biotech re­vives for­mer Ky­owa Kirin can­cer drug for Ep­stein-Barr-dri­ven dis­eases

Ayisha Sharma

News Reporter

Hor­net Ther­a­peu­tics is on a mis­sion to pre­vent and treat con­di­tions re­lat­ed to the Ep­stein-Barr virus (EBV) with the help of a drug can­di­date shelved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times